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Background: Topical high-precision piezo-print delivery of microdoses of latanoprost achieved 
significant IOP reduction consistent with the eyedropper effect but with a 75% reduced exposure 
to drugs and preservatives. Prostaglandin analogs are a mainstay glaucoma therapy. However, 
conventional eyedroppers deliver 30–50 µL drops that greatly exceed the physiologic 7-µL 
ocular tear film capacity. Eyedropper overdosing floods the eye with excess drug compounds and 
preservatives, resulting in ocular surface toxicity, periorbitopathy, and other well-characterized 
ocular side effects. Piezoelectric high-precision microdosing provides targeted delivery that can 
reduce exposure to both drug and preservatives compared to conventional eyedropper delivery, 
with the potential to deliver similar biologic effect.
Methods: Both eyes (N=60) of 30 healthy volunteers received single 8-µL microdoses of 
0.005% latanoprost (0.4 µg; µRx-latanoprost) on the morning of Days 1 and 2 using a high-
precision, piezo-print horizontal delivery system. Diurnal IOP was measured before and 2 days 
after microdosing. Main efficacy outcomes were diurnal IOP change after µRx-latanoprost 
microdosing and accurate microdosing success rates, and the primary safety outcome was 
adverse event (AE) incidence.
Results: µRx-latanoprost reduced baseline IOP by 26% and 30% at 1 and 2 days postadmin-
istration, respectively. Successful topical dosing was achieved in 100% of technician-assisted 
deliveries. All patients successfully self-administered microdoses after receiving training. 
Microdose administration was well tolerated and did not result in any AEs.
Conclusion: Microdosing of 0.4 µg of µRx-latanoprost achieved significant IOP reduction. 
Lower ocular exposure with topical prostaglandin analog microdosing can enable new thera-
peutic opportunities for optimizing glaucoma treatment. Microdosing may also be beneficial 
in reducing ocular side effects associated with excessive drug product and preservatives often 
used to treat chronic ocular diseases such as glaucoma.
Keywords: microdosing, piezo-ejection system, latanoprost, IOP, IOP lowering, glaucoma, 
ocular drug delivery, Optejet, self-administration, usability
Introduction
Conventional eyedroppers deliver large and highly variable macrodoses containing 
30–50 µL of ocular medications. These volumes greatly exceed the reservoir and 
absorptive capacities of the eye, which range between 6 and 8 µL.1–3 Excess medica-
tion volumes are associated with ocular and systemic toxicity,4,5 which in the case of 
prostaglandin analogs include hyperemia, contact dermatitis, pigmentary changes, and 
periorbitopathy.6 With medications having cardiovascular activity, such as β-blockers 
Correspondence: Tsontcho ianchulev
Department of Ophthalmology, 
New York Eye and Ear Infirmary, 
Mount sinai Medical school, Mount 
sinai, 1 gustave l levy Place, Box 1183, 
new York, nY 10029, Usa
Tel +1 617 216 4369
email tianchul@yahoo.com 
Journal name: Clinical Ophthalmology
Article Designation: Original Research
Year: 2018
Volume: 12
Running head verso: Pasquale et al
Running head recto: Latanoprost with high precision, piezo-print microdose
DOI: 185027
Clinical Ophthalmology 2018:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2452
Pasquale et al
(eg, timolol), overflow leakage through the nasolacrimal 
duct with systemic absorption can potentially cause bra-
dycardia, respiratory depression, fatigue, and impotence.4,5 
Drugs entering the body via the nasolacrimal apparatus will 
bypass hepatic first-pass metabolism similar to the intrave-
nous administration, thereby increasing immediate systemic 
bioavailability.4
Reducing the excess volume of topically administered 
ocular medications by improving the precision of micro-
volumetric drug delivery can avoid problems associated 
with drug overflow and systemic absorption that occur after 
conventional eyedropper overdosing. Microdosing may also 
increase local drug bioavailability and absorption in the 
eye. We previously reported on the development of a high 
precision piezo-ejection microdroplet delivery system for 
administering small volumes of topical eye medications.7,8 
This handheld electronic system delivered single-digit 
microliter volumes of topical medication. Results from 
two Phase II clinical trials demonstrated high efficiency of 
topical microdose delivery of ophthalmic mydriatic agents 
(ie, phenylephrine and tropicamide). In these studies, 
microdosing achieved equivalent pharmacodynamic effect 
as conventional eyedropper dosing, but with a 75% reduc-
tion in total drug dose and preservative delivery to the eye. 
High-precision microvolumetric drug delivery also ensures 
on-target delivery without spillage to the periocular regions. 
This is particularly important because only a minority of 
patients are able to accurately self-administer eye drops, even 
after having used them daily for .6 months.9–12
Standard eyedroppers of 0.005% latanoprost (50 µg/mL) 
typically dispense single-drop volumes of 32–34 µL; a 32-µL 
drop contains 1.6 µg of latanoprost. Microdose administra-
tion can deliver a more physiologically appropriate 8-µL 
microdose of 0.005% latanoprost that contains 0.4 µg of 
active drug (µRx-latanoprost). In this clinical trial, we 
evaluated microdosing of antiglaucoma medication using a 
horizontal delivery and piezo-print microdroplet administra-
tion system. We report that µRx-latanoprost microdosing 
significantly lowers IOP while administering only a fraction 
of conventional eyedropper doses.
Methods
subjects, screening, and enrollment
We recruited healthy subjects aged 18 years or older without 
ocular pathology or underlying medical conditions. Female 
subjects of child-bearing age provided a negative serum 
pregnancy test prior to receipt of study medication. The 
study protocol was reviewed and approved by the Panama 
Ministry of Health and the Ethics Committee of Punta 
Pacifica Hospital, which oversaw performance of the study 
at Clinica de Ojos Orillac–Calvo in Panama City, Panama, 
during March 2018. All subjects provided written informed 
consent prior to study participation. Study performance com-
plied with the tenets of the Declaration of Helsinki.
At the screening visit, disease and medication histories 
were collected, and both eyes were examined grossly and 
by slit lamp. Patients who met study eligibility criteria 
underwent baseline unmedicated diurnal IOP measurements 
the day before the initiation of study medication delivery. 
Baseline IOP was measured at approximately 8 AM, 2 PM, 
8 PM, and 7 AM the following day using Goldmann appla-
nation tonometry.
study medication administration
On Days 1 and 2, subjects were administered 0.4 µg 
(8-µL microdose volume) of 0.005% latanoprost bilater-
ally each morning between 7 AM and 9 AM by a trained 
technician. After administration of medication, subjects 
completed ocular discomfort questions and underwent a slit 
lamp examination and diurnal IOP measurements (1, 7, 12, 
and 24 hours after morning microdosing) through 48 hours 
after receiving the first dose. This study was designed to 
investigate short-term diurnal IOP lowering.
During drug administration, the subject sat upright, and 
the technician held the piezo-ejection device approximately 
3–5 cm in front of the eye. The subject was asked to fixate on 
the device’s LED targeting light; then, the dosing button was 
pressed to emit a horizontal microdroplet stream to the eye 
(Figure 1).7,8 After completing the portion of the study in which 
medication effects were observed, subjects were individually 
provided training on microdose self-administration with the 
device to evaluate the rate of successful delivery and only com-
fort (not IOP-lowering effect). The subjects performed three 
consecutive self-administrations on three consecutive days.
Outcome parameters
The primary efficacy outcomes were as follows: 1) mean 
change in short-term diurnal IOP after microdosing with 8 µL 
of µRx-latanoprost; and 2) successful microdose delivery 
rate, which were assessed by the technician administering 
the medication. Successful dosing was defined as accurate 
delivery of the medication to the ocular surface with no 
exposure to periocular tissues or the eyelids during blinking 
or head movement, without any direct physical contact of 
the device to the ocular surface. The primary safety outcome 
was the rate of ocular adverse events (AEs).
Clinical Ophthalmology 2018:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2453
latanoprost with high precision, piezo-print microdose
statistical analyses
Device performance outcomes were analyzed using descrip-
tive statistics. IOP outcomes were analyzed as the mean 
change in diurnal IOP on Day 1 and Day 2 compared to 
premedication baseline diurnal IOP using a paired two-tailed 
t-test, with P,0.05 considered to be a statistically significant 
difference. Left and right eyes of each subject were averaged 
prior to performing calculations to provide a single mean IOP 
value per subject for each time point.
Results
subject selection and demographics
A total of 30 subjects (healthy volunteers) were enrolled and 
received treatment bilaterally. After enrollment, one subject 
was found to have been taking a systemic antihypertensive 
medication and was excluded from IOP analyses due to the 
possible confounding IOP-lowering effect of the systemic 
medication. Thus, 29 subjects (58 eyes) were evaluable for 
IOP analyses. All subjects received pre-protocol treatment 
and completed the study. No subject was discontinued from 
the study due to medical emergency, development of serious 
AEs, use of prohibited medication, or pregnancy.
Mean cohort age was 35.6±10.0 years, with 57% females 
(Table 1). Baseline mean unmedicated diurnal IOP of all 
evaluable subjects was 17.09±0.95 mmHg.
iOP lowering
For the 29 IOP-evaluable subjects, excluding the subject 
on systemic beta-blockers, mean bilateral diurnal IOP was 
reduced from the unmedicated baseline level by 25.7% on 
Day 1 (from 17.1±0.9 to 12.7±1.1 mmHg; P,0.0001) and 
by 29.6% on Day 2 (from 17.1±0.9 to 12.0±1.2 mmHg; 
P,0.0001; Figure 2). Diurnal IOP values significantly 
differed between medicated Days 1 and 2 (P,0.0001). 
The individual IOP measurements at four time points per 
day confirmed this trend (Figure 3). As is standard in IOP-
lowering studies, the outcome was the mean diurnal IOP 
based on the averaged three measurements subsequent to 
treatment. The IOP measured in left and right eyes never 
Table 1 Demographics and medical histories of study subjects
Parameter Value (N=30)
age (years)
Mean±sD
range
35.6±10.0
21.3–58.9
Female, n (%) 17 (57)
Self-identified race, n (%)
White
african american
indian
13 (45)
16 (52)
1 (3)
systemic β-blocker use, n (%) 1 (3)
Ocular medication use, n (%) 0 (0)
Figure 1 The two-part piezo-electric MiDD.
Notes: (A) The small handheld delivery system consists of an exchangeable upper section containing an ampoule reservoir prefilled with sterile ocular medication, which 
snaps into the lower ejection system containing system electronics and battery. (B) On push button activation, the MiDD releases a precisely calibrated and tightly collimated 
stream of aqueous ocular medication microdroplets. The system is designed to reliably administer any selected microdose, which can approach nanoliter scale. The MiDD 
demonstrably administers volumes down to 1.5 µL while maintaining a coefficient of variation below 15% (1.6±0.2 µl; CV=12.5%).7
Abbreviation: MiDD, MicroDose dispenser.
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differed by more than 3 mmHg in any subjects at any time 
point and was within 2 mmHg for .99% of the time (data not 
shown). Diurnal IOP reduction by $20% of baseline diurnal 
IOP occurred in 83% of subjects on postmedication Day 1 
and in 100% of subjects on Day 2 (Figure 4).
Microdose delivery success and comfort
Microdose administration was successful in 100% of 
technician-administered topical treatments (n=150 microdose 
deliveries); 5% of administrations required an additional 
administration because of patient’s blinking or head move-
ment (data not shown). There were no cases of unintentional 
overdosing, tear fluid overflow, or dispenser tip/nozzle touch-
ing the eye. Subjects did not report negligible discomfort 
after µRx latanoprost dosing, and none of the subjects 
experienced ocular discomfort from topical microdroplet 
administration. On a progressive discomfort evaluation scale 
of 0–100 points (with 0 points meaning no discomfort), 
subjects reported scores of 2.0±5.0 points on Day 1, which 
did not significantly change at 3.0±5.0 points on Day 2 
(P=0.638). Investigator-observed subject self-administered 
microdosing was successfully performed by all subjects after 
training, and 88% of self-administrations were successful on 
first attempt with the remaining 12% successfully completed 
on second attempt.
aes
Subjects underwent a slit lamp examination at screening, 
which was repeated on each study drug administration 
day both prior to drug administration and 1 hour postdrug 
administration. No AEs and no clinically significant observa-
tions were reported during any of the slit lamp examinations 
performed during the study. Periocular examination did not 
reveal any effect (eg, eyelid erythema) of mistargeted doses 
in patients who blinked or moved during administration. 
No patient reported stinging, burning, or other irritating 
sensations on delivery of µRx-latanoprost.
Discussion
This study demonstrates the excellent feasibility, effective-
ness, and appropriateness of administering topical microdoses 
of glaucoma medication to the ocular surface using a novel 
system for horizontal, piezo-print microdroplet delivery. 
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Figure 2 Mean diurnal iOP at baseline (unmedicated), Day 1, and Day 2 after 0.4 
µg of 0.005% µrx-latanoprost morning microdosing and percentage change in mean 
diurnal iOP on Day 1 and Day 2 from the baseline.
Note: Data derived from the left/right eye average measurements for 29 evaluable 
subjects.
Figure 3 Mean diurnal iOP for average of left and right eyes after morning 
microdosing with 8 µl of 0.005% µrx-latanoprost (0.4 µg total dose).
Note: n=29 evaluable subjects.
Abbreviations: D, day; h, hour.
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Figure 4 Percent diurnal iOP reduction with 8 µl of 0.005% µrx-latanoprost 
(0.4 µg total dose).
Note: n=29 evaluable subjects.
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The high clinical performance of the system for topical drug 
delivery is further demonstrated by a significant correspond-
ing pharmacodynamic effect of using µRx-latanoprost to 
lower IOP.
Microdosing system delivery was successful for all 
patients when performed by a technician in the office setting. 
Almost all of the cases requiring additional study medication 
administration occurred on the initial drug administration 
day and are considered to be a function of the technician’s 
learning curve related to counseling patients on eye align-
ment. Subject self-administration after receipt of training 
was similarly successful. In all successful topical administra-
tions with the microdroplet spray, no part of the MicroDose 
dispenser (MiDD) touched the eye or the periocular area. 
In comparison, studies of conventional eyedropper delivery 
demonstrate significant variability in dosing administration 
efficacy.9–16 Even in experienced eye drop users who had been 
prescribed and had used eye drops for more than 6 months, 
20% of “compliant” patients missed their eye entirely on 
the first attempt, with most failing to realize that they had 
missed the dose.11 In another study, glaucoma patients used 
an average of 1.8±1.2 drops (range, 1–8 drops) in each 
ultimately successful attempt,9 most of which was wasted 
outside the eye; this may explain why many patients run 
out of their drops well ahead of their monthly prescription 
period. In these studies, patients accurately self-delivered 
the prescribed dose in only 7%–39% of attempts.9–13 About 
33%–76% of patients touched their periocular tissue or the 
globe with the eye drop bottle tip.9,10,12 An eyedropper tip 
touching the ocular surface can cause corneal abrasions, 
and contact with either the globe or surrounding tissues 
can cause eyedropper bottle contamination with bacteria. 
One study reported that bacterial contamination occurred in 
19% of eye drops used for ,8 weeks and in 40% of bottles 
used .8 weeks.17 In the elderly, the problem is even more 
palpable: one study reported that one-third of the surveyed 
persons aged 75 years or older living alone and more than half 
of those applying eye drops by themselves did so with poor 
success.14 Even in more functional healthy patients undergo-
ing routine cataract surgery and who were prescribed several 
weeks of postoperative eye drops, 92% displayed improper 
administration technique including missing the eye (31%), 
incorrect instillation amount (64%), and contamination of 
the bottle (57%).15
Patients consistently rated microdosing to be essentially 
without discomfort. No reported or investigator-identified 
AEs occurred. These findings are congruent with earlier 
demonstrations of the excellent utility of the MiDD system 
for comfortably delivering multiple 8-µL microdoses of other 
ocular medications (eg, phenylephrine).7,8
The results of this clinical trial of µRx-latanoprost dem-
onstrated a high success rate of ocular microdose delivery, 
further evidenced by the robust IOP-lowering effect of 
microdosing at a fraction of the volume and total therapeutic 
dose of standard eye drops (75% lower than conventional 
eyedropper doses) with almost 30% reduction in diurnal 
IOP through 48 hours in once daily microdosed healthy 
volunteers. The occurrence of 13% additional diurnal IOP-
lowering effect (absolute IOP difference of 5%) on Day 2 
compared to that on Day 1 may indicate an incrementally 
increasing effect in the first days of µRx-latanoprost delivery, 
and a long-term IOP reduction with microdosing might result 
in even further IOP reduction after stabilization of cumulative 
ocular responses. Future investigations are needed to study 
the long-term response.
Our IOP-lowering findings are consistent with the effect 
previously reported in the peer-reviewed literature using 
standard eyedropper-delivered 0.005% latanoprost in a similar 
setting of healthy volunteers. In one study of 28 healthy volun-
teers, conventional eyedropper-administered 0.005% latano-
prost achieved 26% IOP-lowering effect in the first 2 days.17 
Similarly, in another study, eyedropper-delivered 0.005% 
latanoprost achieved 24% IOP-lowering effect in healthy 
volunteers.18 Thus, our 26% Day 1 and 30% Day 2 IOP-
lowering effects with µRx-latanoprost are consistent with the 
level of IOP reduction previously reported after eyedropper 
overdosing of approximately fourfold larger total latanoprost 
doses. The significance of the diurnal IOP values differences 
between medicated Days 1 and 2 (P,0.0001) indicate that 
there could be further IOP reduction with long-term treatment 
until reaching a stable and minimum IOP trough.
This study further confirms the growing evidence from 
peer-reviewed literature that clinically meaningful thera-
peutic effect can be achieved by using smaller fractional 
doses of topical medications that spare the eye from drug 
and preservative overdose. Microvolumes as low as 2–5 µL 
have demonstrated compelling pharmacodynamic effect 
similar to conventional overdosing with eye drops.19–21 More 
physiologic microdosing studies that better match the tear 
film capacity of 6–8 µL have also demonstrated high potency 
and biologic effect.22–24
The current study, along with the two prior clinical trials 
of piezo-print microdosing,7,8 demonstrates a broad range 
of therapeutic applicability of ocular drug delivery with a 
high-precision horizontal microjet. The ocular microdosing 
approach can produce an equivalent biologic effect compared 
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to established eyedropper therapies while improving dosing 
precision, accuracy, and delivery success rate. This study 
expands our understanding of biologically appropriate dosing 
for front-of-the-eye therapies and further suggests the useful-
ness of microdosing to improve the therapeutic index of many 
topically administered ocular pharmacologics.
Despite the new clinical insights and the informative 
nature of this study, its limitations are the short-term nature 
of the patient’s follow-up and the healthy volunteer office-
based setting that may not be representative of other patient 
populations and long-term home use. Although the biologic 
effect of microdosed latanoprost on IOP-lowering effect is 
significant, this study did not directly compare microdosing 
of 0.4 µg of µRx-latanoprost to 1.6 µg dosing of standard 
eyedropper in a randomized controlled fashion, which we 
plan to do in future studies.
In conclusion, ocular microdosing with high-precision 
piezo-ejection delivery systems can be easily performed 
by a technician or a patient with a high rate of success. 
Microdosing of an 8-µL drop volume containing 0.4 µg of 
µRx-latanoprost achieved comparable IOP reduction with 
the levels previously observed with eyedropper overdosing. 
Lower ocular exposure with topical prostaglandin analog 
microdosing can enable new therapeutic opportunities for 
optimizing glaucoma treatment. Microdosing may be useful 
for reducing ocular overexposure to other ophthalmic drugs 
that are used to treat various other ocular diseases.
Future perspectives
Eyenovia’s high-precision piezo-print microdosing approach 
is widely applicable for treating many front-of-the-eye 
diseases such as glaucoma, dry eye, allergic eye disease, 
and many ocular pathologies with infectious and immuno-
logic etiologies. Topical side effects such as conjunctival 
hyperemia, discomfort, irritation, prostaglandin-associated 
periorbitopathy are dose related and can be significantly 
reduced with high-precision targeted microdosing. Also, the 
electronic piezo-delivery platform opens immense possibili-
ties for eHealth and patient monitoring, compliance tracking, 
and customized treatment approaches.
executive summary
Conventional eyedroppers deliver oversized doses 
that exceed the eye’s absorptive and storage 
capacities
•	 Trigger reflex blinking and tearing.
	 Drug loss to spillage and increased drainage.
	 Medication dilution from tearing.
•	 Overflow can irritate skin and eyelids.
•	 Nasolacrimal mucosal absorption can cause systemic side 
effects.
	 No hepatic first-pass metabolism.
	 Cardiopulmonary and neurological risks with common 
topical ocular medications.
	 Children and elderly are at particularly high risk of 
systemic AEs.
Piezoelectric delivery can precisely deliver 
single-microliter microdoses
•	 Overflow, ocular irritation, and reflex blinking/tearing 
reduced.
	 Less drug loss and medication dilution.
	 Increased bioavailability to the eyes.
	 Reduced local drug reactions.
	 User friendliness may increase compliance with 
ocular dosing regimens.
•	 Systemic drug absorption and related side effect risk are 
decreased.
Microdosing delivers robust iOP-lowering effect with 
µrx latanoprost at a fraction of the dose
•	 Almost 30% diurnal IOP-lowering effect over 2 days 
with single 0.4 µg dose (a quarter of conventional 
eyedropper).
•	 Piezoelectric microdosing technology may be modified 
to deliver glaucoma and dry eye medications, antibiotics, 
analgesics, biologics, gene therapy vectors, nanoparticles, 
and corneal/limbal stem cells.
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